LIVIVO - Search results -

Search results

Result 1 - 10 of total 26

Search options

Article ; Online: Androgen Deprivation Fortified.

Mendiratta, Prateek / Garcia, Jorge

International journal of radiation oncology, biology, physics

2018 Volume 100, Issue 5, Page(s) 1098

MeSH term(s)	Androgen Antagonists ; Humans ; Male ; Neoplasm Recurrence, Local ; Prostatic Neoplasms
Chemical Substances	Androgen Antagonists
Language	English
Publishing date	2018-05-03
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	197614-x
ISSN	1879-355X ; 0360-3016
ISSN (online)	1879-355X
ISSN	0360-3016
DOI	10.1016/j.ijrobp.2018.01.103
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review.

Patell, Kanchi / Kurian, Matthew / Garcia, Jorge A / Mendiratta, Prateek / Barata, Pedro C / Jia, Angela Y / Spratt, Daniel E / Brown, Jason R

Expert review of anticancer therapy

2023 Volume 23, Issue 7, Page(s) 731–744

Abstract: Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications, many patients ... ...

Abstract	Introduction: Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive form of prostate cancer that no longer responds to traditional hormonal treatment alone. Despite the advent of novel anti-androgen medications, many patients continue to progress, and as a result, there is a growing need for additional treatment options. Areas covered: Lutetium-177 ( Expert opinion: 177
MeSH term(s)	Male ; Humans ; Prospective Studies ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Radioisotopes ; Prostate-Specific Antigen ; Treatment Outcome
Chemical Substances	Lutetium-177 (BRH40Y9V1Q) ; Radioisotopes ; Prostate-Specific Antigen (EC 3.4.21.77)
Language	English
Publishing date	2023-05-24
Publishing country	England
Document type	Systematic Review ; Journal Article ; Review
ZDB-ID	2112544-2
ISSN	1744-8328 ; 1473-7140
ISSN (online)	1744-8328
ISSN	1473-7140
DOI	10.1080/14737140.2023.2213892
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5907: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Emerging biomarkers and targeted therapies in urothelial carcinoma.

Mendiratta, Prateek / Grivas, Petros

Annals of translational medicine

2018 Volume 6, Issue 12, Page(s) 250

Abstract: The use of immunotherapy has revolutionized the management of patients with locally advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum-based chemotherapy remains a therapeutic cornerstone both in localized muscle-invasive ...

Abstract	The use of immunotherapy has revolutionized the management of patients with locally advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum-based chemotherapy remains a therapeutic cornerstone both in localized muscle-invasive and advanced UC. There is still no predictive molecular biomarker with clinical utility to help guide treatment and select patients most likely to derive benefit from a particular therapeutic modality or regimen. However, recent research has further characterized the inherent biology and immunology landscapes of UC leading to the development of potential biomarkers and therapeutic targets that could be used upon further validation. Emerging interrogation of The Cancer Genome Atlas (TCGA) and other molecular profiling datasets has led to the identification of distinct molecular subtypes with diverse clinical behaviors with potential sensitivity to various therapies. It has also led to the discovery of multiple frequently altered genes and proteins that could lead to perturbation of intracellular signaling pathways and of the dynamic interactions between tumor cells, their "microenvironment", and the host "macro-environment". The advent of molecular profiling and deeper next-generation sequencing has the potential to change biomarker and "real time" drug sensitivity assessment, introducing and testing the premise of "precision oncology" and personalized medicine. Within this review, we summarize emerging biomarkers that may predict response to cisplatin-based chemotherapy, immunotherapy, emerging targeted therapies, and promising combination strategies. We also highlight a few examples of 'precision medicine' trials aiming to improve outcomes in UC. Since our review is not exhaustive we strongly recommend the readers to follow the continuously changing literature in the very interesting and dynamic field of UC.
Language	English
Publishing date	2018-07-04
Publishing country	China
Document type	Journal Article ; Review
ZDB-ID	2893931-1
ISSN	2305-5847 ; 2305-5839
ISSN (online)	2305-5847
ISSN	2305-5839
DOI	10.21037/atm.2018.05.49
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Retrospective Outcomes of a New Acupuncture Service at a Comprehensive Cancer Center.

Shi, Yuming / Nguyen, Thuy / Farrell, Megan / Rodgers-Melnick, Samuel / Moss, Gabriel / Kaiser, Christine / Dusek, Jeffery A / Mendiratta, Prateek / Adan, Francoise / Lee, Richard T

Journal of integrative and complementary medicine

2023 Volume 29, Issue 10, Page(s) 674–682

Abstract: Introduction: ...

Abstract	Introduction:
MeSH term(s)	Humans ; Sleep Initiation and Maintenance Disorders ; Retrospective Studies ; Activities of Daily Living ; Anorexia ; Pain ; Acupuncture Therapy ; Constipation/therapy ; Nausea/etiology ; Nausea/therapy ; Neoplasms/complications ; Neoplasms/therapy
Language	English
Publishing date	2023-05-26
Publishing country	United States
Document type	Journal Article
ISSN	2768-3613
ISSN (online)	2768-3613
DOI	10.1089/jicm.2022.0709
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.

Roy, Soumyajit / Saad, Fred / Malone, Shawn / Agarwal, Neeraj / Mohamad, Osama / Morgan, Scott C / Malone, Julia / Swami, Umang / Jia, Angela Y / Gebrael, Georges / Mendiratta, Prateek / Brown, Jason R / Rao, Santosh K / Sun, Yilun / Wallis, Christopher J D / Chi, Kim N / Chowdhury, Simon / Kishan, Amar U / Spratt, Daniel E

European urology

2024 Volume 85, Issue 4, Page(s) 398–400

MeSH term(s)	Male ; Humans ; Prostate/pathology ; Prostatic Neoplasms/pathology ; Thiohydantoins/therapeutic use ; Hormones ; Prostatic Neoplasms, Castration-Resistant/pathology ; Androgen Antagonists/therapeutic use
Chemical Substances	apalutamide ; Thiohydantoins ; Hormones ; Androgen Antagonists
Language	English
Publishing date	2024-02-15
Publishing country	Switzerland
Document type	Letter
ZDB-ID	193790-x
ISSN	1873-7560 ; 1421-993X ; 0302-2838
ISSN (online)	1873-7560 ; 1421-993X
ISSN	0302-2838
DOI	10.1016/j.eururo.2024.01.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1247: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 294: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation.

Mendiratta, Prateek / Rini, Brian I / Tendulkar, Rahul D

Urology

2017 Volume 113, Page(s) e1–e2

Abstract: Urethral adenocarcinoma of males is a rare disease with limited prospective data to define optimal treatment. Surgical excision remains the primary treatment for early-stage disease. Multimodality therapy with a combination of chemotherapy, radiation, or ...

Abstract	Urethral adenocarcinoma of males is a rare disease with limited prospective data to define optimal treatment. Surgical excision remains the primary treatment for early-stage disease. Multimodality therapy with a combination of chemotherapy, radiation, or surgery has been explored in patients with locally advanced disease. We present the case of a 45-year-old-man with a locally recurrent urethral adenocarcinoma after initial surgical resection managed successfully with combined weekly cisplatinum and radiation therapy.
MeSH term(s)	Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Chemoradiotherapy/methods ; Cisplatin/therapeutic use ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Organ Sparing Treatments/methods ; Time Factors ; Treatment Outcome ; Urethral Neoplasms/diagnostic imaging ; Urethral Neoplasms/pathology ; Urethral Neoplasms/surgery
Chemical Substances	Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2017-12-02
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	192062-5
ISSN	1527-9995 ; 0090-4295
ISSN (online)	1527-9995
ISSN	0090-4295
DOI	10.1016/j.urology.2017.11.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 275: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The modern therapeutic & imaging landscape of metastatic prostate cancer: a primer for radiologists.

Yoon, Justin G / Mohamed, Inas / Smith, Daniel A / Tirumani, Sree H / Paspulati, Raj M / Mendiratta, Prateek / Ramaiya, Nikhil H

Abdominal radiology (New York)

2021 Volume 47, Issue 2, Page(s) 781–800

Abstract: Prostate cancer represents one of the leading causes of cancer-related mortality in the United States and the most common cancer among men. Treatment paradigms for the management of advanced stages of prostate cancer have continued to evolve in recent ... ...

Abstract	Prostate cancer represents one of the leading causes of cancer-related mortality in the United States and the most common cancer among men. Treatment paradigms for the management of advanced stages of prostate cancer have continued to evolve in recent years. These advancements in the therapeutic landscape of metastatic prostate cancer and diagnostic imaging modalities have fundamentally changed the treatment of patients with prostate cancer. In this review article we provide a primer for radiologists highlighting the most recent developments in treatment options and imaging techniques utilized in the modern oncologic management of metastatic prostate cancer. We will examine current therapy options and associated toxicities with an emphasis on relevant imaging findings commonly encountered by radiologists. We also summarize the role of modalities including CT, MRI, PET, bone scintigraphy, and PET in the diagnosis and follow-up of patients with metastatic prostate cancer.
MeSH term(s)	Humans ; Magnetic Resonance Imaging ; Male ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/therapy ; Radiologists
Language	English
Publishing date	2021-11-16
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2839786-1
ISSN	2366-0058 ; 2366-004X
ISSN (online)	2366-0058
ISSN	2366-004X
DOI	10.1007/s00261-021-03348-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1262: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Emerging immunotherapy in advanced renal cell carcinoma.

Mendiratta, Prateek / Rini, Brian I / Ornstein, Moshe C

Urologic oncology

2017 Volume 35, Issue 12, Page(s) 687–693

Abstract: Immunotherapy has recently catapulted to the forefront of treatments for patients with solid tumors. Given its inherent immunogenic properties, renal cell carcinoma (RCC) has historically responded to immunotherapy and remains primed for further ... ...

Abstract	Immunotherapy has recently catapulted to the forefront of treatments for patients with solid tumors. Given its inherent immunogenic properties, renal cell carcinoma (RCC) has historically responded to immunotherapy and remains primed for further development. Although immunotherapy with high-dose interleukin 2 was a primary treatment for advanced RCC (aRCC), recent discoveries of key molecular and immunological alterations have led to the FDA-approval of nivolumab, an antiprogrammed cell death inhibitor, which has demonstrated an overall survival in patients with previously treated aRCC. However, despite recent therapeutic advances, aRCC remains an incurable disease for most patients. In this review, we assess the current landscape and future developments of immunotherapy in aRCC.
MeSH term(s)	Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/immunology ; Antineoplastic Agents/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; B7-H1 Antigen/metabolism ; Carcinoma, Renal Cell/immunology ; Carcinoma, Renal Cell/pathology ; Carcinoma, Renal Cell/therapy ; Disease-Free Survival ; Humans ; Immunotherapy/methods ; Interleukin-2/immunology ; Interleukin-2/therapeutic use ; Kidney Neoplasms/immunology ; Kidney Neoplasms/pathology ; Kidney Neoplasms/therapy ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Programmed Cell Death 1 Receptor/metabolism
Chemical Substances	Antibodies, Monoclonal ; Antineoplastic Agents ; B7-H1 Antigen ; CD274 protein, human ; Interleukin-2 ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; nivolumab (31YO63LBSN)
Language	English
Publishing date	2017
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1336505-8
ISSN	1873-2496 ; 1078-1439
ISSN (online)	1873-2496
ISSN	1078-1439
DOI	10.1016/j.urolonc.2017.08.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4817: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.

Jang, Albert / Lanka, Sree M / Jaeger, Ellen B / Lieberman, Alexandra / Huang, Minqi / Sartor, A Oliver / Mendiratta, Prateek / Brown, Jason R / Garcia, Jorge A / Farmer, Tiffany / Sudhaman, Sumedha / Mahmood, Tamara / Pajak, Natalia / Calhoun, Mark / Dutta, Punashi / ElNaggar, Adam / Liu, Minetta C / Barata, Pedro C

JCO precision oncology

2023 Volume 7, Page(s) e2300131

Abstract: Purpose: Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response in patients receiving immune checkpoint inhibitors (ICIs). Here, we performed a pilot ... ...

Abstract	Purpose: Circulating tumor DNA (ctDNA) detection in blood has emerged as a prognostic and predictive biomarker demonstrating improved assessment of treatment response in patients receiving immune checkpoint inhibitors (ICIs). Here, we performed a pilot study to support the role of ctDNA for longitudinal treatment response monitoring in patients with advanced genitourinary (GU) malignancies receiving ICIs. Materials and methods: Patients with histologically confirmed advanced GU malignancies were prospectively enrolled. All eligible patients received ICI treatment for at least 12 weeks, followed by serial collection of blood samples every 6-8 weeks and conventional scans approximately every 12 weeks until disease progression. ctDNA analysis was performed using Signatera, a tumor-informed multiplex-polymerase chain reaction next-generation sequencing assay. Overall, the objective response rate (ORR) was reported and its association with ctDNA status was evaluated. Concordance rate between ctDNA dynamics and conventional imaging was also assessed. Results: ctDNA analysis was performed on 98 banked plasma samples from 20 patients (15 renal, four urothelial, and one prostate). The median follow-up from the time of initiation of ICI to progressive disease (PD) or data cutoff was 67.7 weeks (range, 19.6-169.6). The ORR was 70% (14/20). Eight patients ultimately developed PD. The overall concordance between ctDNA dynamics and radiographic response was observed in 83% (15/18) of patients. Among the three patients with discordant results, two developed CNS metastases and one progressed with extracranial systemic disease while ctDNA remained undetectable. Conclusion: In this pilot study, longitudinal ctDNA analysis for monitoring response to ICI in patients with advanced GU tumors was feasible. Larger prospective studies are warranted to validate the utility of ctDNA as an ICI response monitoring tool in patients with advanced GU malignancies.
MeSH term(s)	Male ; Humans ; Circulating Tumor DNA/genetics ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Pilot Projects ; Neoplasms ; Urogenital Neoplasms/drug therapy ; Urogenital Neoplasms/genetics
Chemical Substances	Circulating Tumor DNA ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2023-07-19
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.23.00131
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer.

Barata, Pedro C / Cooney, Matthew / Mendiratta, Prateek / Gupta, Ruby / Dreicer, Robert / Garcia, Jorge A

Investigational new drugs

2018 Volume 37, Issue 2, Page(s) 331–337

Abstract: Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through vascular endothelial growth factor (VEGF) have been shown to play important roles in prostate cancer progression. Preclinical data in prostate cancer has suggested the ... ...

Abstract	Background Mammalian target of rapamycin (mTOR) pathway and angiogenesis through vascular endothelial growth factor (VEGF) have been shown to play important roles in prostate cancer progression. Preclinical data in prostate cancer has suggested the potential additive effect dual inhibition of VEGF and mTOR pathways. In this phase I/II trial we assessed the safety and efficacy of bevacizumab in combination with temsirolimus for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Methods In the phase I portion, eligible patients received temsirolimus (20 mg or 25 mg IV weekly) in combination with a fixed dose of IV bevacizumab (10 mg/kg every 2 weeks). The primary endpoint for the phase II portion was objective response measured by either PSA or RECIST criteria. Exploratory endpoints included changes in circulating tumor cells (CTC) and their correlation with PSA response to treatment. Results Twenty-one patients, median age 64 (53-82), with pre-treatment PSA of 205.3 (11.1-1801.0), previously treated with a median of 2 (0-5) lines of therapy for mCRPC received the combination of temsirolimus weekly at 20 mg (n = 4) or 25 mg (n = 17) with bevacizumab 10 mg/kg every 2 weeks (n = 21). Median time to progression was 2.6 months (95% CI, 1.2-3.9) and the median best PSA change from baseline to 12 weeks was a 32% increase (-40-632%) which met the predefined futility rule and led to early termination of the study. Nine patients (43%) had ≥ grade 3 toxicity that included fatigue (24%), anorexia (10%), nausea/vomiting (5%) and lymphopenia (5%). In exploratory analysis, a decrease in CTC levels was observed in 9 out of 11 patients. No association between PSA levels and CTC levels was detected. Conclusions The combination of temsirolimus and bevacizumab showed limited clinical activity in mCRPC patients previously treated with chemotherapy and was associated with significant adverse events (AEs). Transient decrease in CTC levels was independent from PSA response. NCT01083368.
MeSH term(s)	Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzodiazepines/chemistry ; Bevacizumab/administration & dosage ; Biomarkers, Tumor/metabolism ; Disease Progression ; Drug Resistance, Neoplasm/drug effects ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Prostatic Neoplasms, Castration-Resistant/pathology ; Pyrroles/chemistry ; Salvage Therapy ; Sirolimus/administration & dosage ; Sirolimus/analogs & derivatives ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Tissue Distribution ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Chemical Substances	Biomarkers, Tumor ; Pyrroles ; VEGFA protein, human ; Vascular Endothelial Growth Factor A ; pyrrolo(2,1-c)(1,4)benzodiazepine ; Benzodiazepines (12794-10-4) ; Bevacizumab (2S9ZZM9Q9V) ; temsirolimus (624KN6GM2T) ; MTOR protein, human (EC 2.7.1.1) ; TOR Serine-Threonine Kinases (EC 2.7.1.1) ; Sirolimus (W36ZG6FT64)
Language	English
Publishing date	2018-11-07
Publishing country	United States
Document type	Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Multicenter Study
ZDB-ID	604895-x
ISSN	1573-0646 ; 0167-6997
ISSN (online)	1573-0646
ISSN	0167-6997
DOI	10.1007/s10637-018-0687-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1823: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito